Definium Therapeutics, a late‑stage biopharmaceutical firm headquartered in New York, announced a webcast for Monday at 8:00 a.m. EDT to present the primary results of its Panorama Phase 3 study of DT120 oral disintegrating tablet (ODT) in adults with generalized anxiety disorder.
The multicenter, randomized, double‑blind, placebo‑controlled trial enrolled 245 participants aged 18 to 74 at roughly 32 sites. Subjects were allocated in a 2:1:2 ratio to receive a single dose of DT120 ODT 100 µg, DT120 ODT 50 µg, or matching placebo. The study comprised a 12‑week double‑blind treatment phase followed by a 40‑week open‑label extension, during which participants could receive up to four additional 100 µg doses based on symptom severity.
The primary efficacy endpoint is the change from baseline in the Hamilton Anxiety Rating Scale (HAM‑A) total score at Week 12. Key secondary endpoints include the change from baseline in the Clinical Global Impression‑Severity (CGI‑S) score at Week 12, the HAM‑A score change at Week 1, and the CGI‑S score change at Day 2.
A replay of the webcast will be available on Definium’s investor‑relations website for at least 30 days.
